SOURCE: Xtalks

Xtalks Webinars

April 04, 2016 07:00 ET

Patient-Derived Xenografts of Hematological Malignancies: Model Systems for Drug Development and Tumor Biology Research, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - April 04, 2016) - In this session, Julia Schueler, Department Head of In Vivo Tumor Biology at Oncotest GmbH, and Megan MacBride, Associate Director of Product Management at Taconic Biosciences, will discuss how hematological patient-derived xenograft (PDX) models are established, why hematological PDX models are more translational than cell line-derived models, and how they can be employed in drug discovery and development. The live broadcast takes place on Thursday, April 14, 2016 at 11am EDT (4pm BST/UK).

In recent years, there have been multiple efforts in the establishment and characterization of large collections of Patient-Derived Tumor Xenograft (PDX) models for cancer research. Although this model system was developed already in the late 1980´s, it has come into focus lately due to its predictivity for clinical outcome and utility in biomarker development. PDX models mainly retain the histological and genetic characteristics of the donor tumor and remain stable across passages. They preserve cell-autonomous heterogeneity thereby representing very well the molecular landscape of the corresponding disease. Since triple immune deficient mouse strains like NOD/Shi-scid/IL-2Rγ null (NOG) mice were made available to the scientific community; PDX of hematological malignancies could be established to a similar extent as their solid counterparts. Despite the incontrovertible advantages of PDX as preclinical models in drug development, pharma research faces a high failure rate combined with the rising cost of research and the development of new drugs particularly in early clinical development. In view of success rates below 5% for innovative cancer drugs, improvements in model development are urgently needed.

Key learning points:

  • How hematological patient-derived xenograft (PDX) models are established
  • How more super immune deficient mouse models have advanced development of hematological PDX models
  • Why hematological PDX models are more translational than cell line-derived models
  • How hematological PDX models can be employed in drug discovery and development

To learn more about this complimentary event visit: Patient-derived Xenografts of Hematological Malignancies: Model Systems for Drug Development and Tumor Biology Research

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx

Image Available: http://www.marketwire.com/library/MwGo/2016/4/1/11G091467/Images/taconic_stacked_process_small-a31dded0a208a1beb4063b68d354ad34.jpg

Contact Information